小构树醇B | 99624-27-8

• 物质功能分类: 天然产物 - 黄酮类化合物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 中文名称: 小构树醇B
• 中文别名: 小构树醇 B
• 英文名称: kazinol B
• 英文别名: 6-[(2S)-7-hydroxy-3,4-dihydro-2H-chromen-2-yl]-2,2-dimethyl-7-(3-methylbut-2-enyl)chromen-8-ol
• CAS: 99624-27-8
• 化学式: C₂₅H₂₈O₄
• 分子量: 392.495
• InChiKey: QSCBHDIGHKHWKC-NRFANRHFSA-N

物化性质

• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  4

制备方法与用途

小构树醇B提取自桑科植物构树，常用于含量测定、鉴定以及药理实验。

反应信息

• 作为反应物：
  描述：

  硫酸二甲酯 、 小构树醇B 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 2.0h， 以19 mg的产率得到kazinol B dimethyl ether
  参考文献：
  名称：

  Ikuta, Junko; Hano, Yoshio; Nomura, Taro, Heterocycles, 1985, vol. 23, # 11, p. 2835 - 2842

  摘要：

  DOI：
• 作为产物：
  描述：

  kazinol B 在 Daicel Chiralpak AD-H chiral column 作用下， 以 正己烷 、 异丙醇 为溶剂， 以3.4 mg的产率得到小构树醇B
  参考文献：
  名称：

  自噬可拮抗达芙妮（Daphne giraldii）的黄烷对映体诱导的肝癌细胞凋亡。

  摘要：

  对映异构体在天然产物中占很大比例的化合物。我们的团队对外消旋化合物的分离和生物活性感兴趣。在本报告中，从达芙妮（Daphne giraldii）的茎和根皮中分离出四对异戊烯基黄烷对映体[（±）-1-（±）-4]，包括五种新化合物，并通过手性色谱柱成功分离。通过全面的光谱分析以及圆二色性（CD）光谱确定了它们的平面结构和绝对构型。分离株对肝癌细胞系具有选择性的细胞毒性。其中，新化合物（+）-4与其外消旋混合物4相比，对Hep3B细胞的抑制作用更强，IC50值为30.3μM。因此，随后研究了（+）-4在体外的作用机理。形态学观察和蛋白质印迹分析表明，（+）-4可以通过内在和外在途径显着诱导凋亡，并通过增加Hep3B细胞中AMP激活的蛋白激酶（AMPK）的磷酸化而引起自噬。用自噬抑制剂bafilomycin A1（Baf A1）治疗后，（+）-4诱导的细胞凋亡显着增加，表明（+）-4诱导的自噬对凋亡细胞死亡具有保护作用。

  DOI：

  10.1016/j.ejmech.2017.03.072

文献信息

• Comprehensive nutraceutical agent for treatment/ prevention of Parkinson's disease
  申请人：Mazzio Elizabeth

  公开号：US20070116779A1

  公开（公告）日：2007-05-24

  This invention discloses a comprehensive nutraceutical designed to antagonize major mitigating factors specific to the degenerative process that occurs in Parkinson's disease (PD). The formulation is comprised of pyruvate, succinate and/or oxaloacetate further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The formula is based on means to attenuate the loss of ATP/toxicity by PD model toxins: 1-methyl-4-phenylpyridinium and rotenone, scavenge hydrogen peroxide/O 2 , augment antioxidant enzymes, prevent dopamine oxidation to DA-quinone via inhibition of COX, PLA 2 , LOX, xanthine oxidase, tyrosinase, prevent hyperhomocysteinemia, antagonize PARP-1 apoptosis, increase blood flow, glucose and oxygen delivery to the brain, potentiate mitochondrial function, antagonize glia iNOS and MAO or its products, chelate redox-active iron, inhibit hemeoxygenase-1, inhibit alpha-synuclein aggregation, augment ATP storage, mediate anti-inflammatory effects via inhibition. of PDE, MAPK p38/c-Jun NH2-terminal kinase/PGE2, antagonize excitotoxicity and downregulate N-methyltransferase, all of which contribute toward PD pathology.
• Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
  申请人：Mazzio Elizabeth

  公开号：US20080292607A1

  公开（公告）日：2008-11-27

  This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate and/or oxaloacetate, fruit extracts and anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains substances that should attenuate the loss of ATP/toxicity by PD model toxins: 1-methyl-4-phenylpyridinium and rotenone, scavenge hydrogen peroxide/O 2 . − , augment antioxidant enzymes, prevent dopamine (DA) oxidation to DA-quinone via inhibition of COX, PLA 2 , LOX, xanthine oxidase, tyrosinase, prevent hyperhomocysteinemia, antagonize PARP-1 apoptosis, increase blood flow, glucose and oxygen delivery to the brain, potentiate mitochondrial function, antagonize glia iNOS and MAO or its products, chelate redox-active iron, inhibit heme oxygenase-1, inhibit alpha-synuclein aggregation, augment ATP storage, mediate anti-inflammatory effects via inhibition of PDE, MAPK p38/c-Jun NH2-terminal kinase/PGE2, antagonize excitotoxicity and downregulate N-methyltransferase, all of which contribute toward PD pathology.
• Nutraceutical agent for attenuating the Neurodegenerative process associated with Parkinson's disease
  申请人：Mazzio Elizabeth

  公开号：US20100150895A1

  公开（公告）日：2010-06-17

  This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate, α-Ketoglutarate and/or oxaloacetate, niacin/NADH, fruit extracts, anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains all natural substances that should mitigate many of the neurodegenerative processes known to be associated with PD. Mechanisms addressed are to prevent the loss of ATP/by 1-methyl-4-phenylpyridinium rotenone, scavenge hydrogen peroxide/O 2 . − , augment antioxidant enzymes, prevent dopamine (DA) oxidation to DA-quinone via inhibition of COX, PLA 2 , LOX, xanthine oxidase, tyrosinase, prevent hyperhomocysteinemia, antagonize PARP-1 apoptosis, increase blood flow, glucose and oxygen delivery to the brain, potentiate mitochondrial function, antagonize glia iNOS and MAO or its products, chelate redox-active iron, inhibit heme oxygenase-1, inhibit alpha-synuclein aggregation, augment ATP storage, mediate anti-inflammatory effects via inhibition of PDE, MAPK p38/c-Jun NH2-terminal kinase/PGE2, antagonize excitotoxicity and downregulate N-methyltransferase, all of which contribute toward PD pathology.
• US8367121B2
  申请人：——

  公开号：US8367121B2

  公开（公告）日：2013-02-05